The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1313
Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A new fixed-dose tablet (PrandiMet – Novo Nordisk) combining metformin (Glucophage, and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for patients not adequately controlled on either drug alone.

FIXED-DOSE COMBINATIONS — When patients with diabetes require more than one drug to achieve glycemic goals, most clinicians prescribe a second drug with a different mechanism of action.1 Metformin, which is often the first drug used, is already available in fixed-dose combinations with the sulfonylureas glipizide (Metaglip, and others) and glyburide (Glucovance, and others), with the thiazolidinediones pioglitazone (Actoplus Met) and rosiglitazone (Avandamet), and with the DPP-4 inhibitor sitagliptin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Metformin Repaglinide (PrandiMet) for Type 2 Diabetes
Article code: 1313b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian